New research from Spherix Global Insights reveals that access barriers, not drug efficacy, restrict the use of Ardelyx's Xphozah for dialysis patients with hyperphosphatemia. Nephrologists say they would nearly triple Xphozah prescriptions if reimbursement and coverage obstacles were removed. However, physicians also overestimate how well phosphorus levels are controlled and how often combination therapies are used. As the Transitional Drug Add-on Payment Adjustment (TDAPA) ends in 2026, reimbursement changes may further impact phosphate-lowering therapy markets. The study highlights a gap between treatment potential and real-world use, with dietitians playing a key role in therapy decisions and gastrointestinal side effects affecting patient persistence on Xphozah.
Circle has introduced a new borrowing service for institutional clients that allows them to use Bitcoin as collateral to borrow USDC without selling their BTC holdings. The service operates on the Arc and Ethereum networks through Circle Mint account...
An Ethereum ICO-era whale purchased 8,492.8 ETH worth $23.7 million at an average price of $2,794 on September 21, marking a return to the market after six months. This buying helped push Ethereum's price above $2,800 for the first time since January...
Dutch police arrested two men suspected of using counterfeit EURC stablecoins to fraudulently obtain Rolex watches from sellers on Marktplaats, a major Dutch online marketplace. The fake tokens appeared genuine in wallets, tricking sellers into relea...
Agree Realty Corporation maintains a robust portfolio of 2,824 retail properties and strong credit metrics, including a low secured debt ratio and high asset coverage. Its common stock trades at a 1.34x price-to-book with a 5.21% AFFO yield, supporti...
Ethereum (ETH) has surged past the $2,700 mark, trading at $2,716.86 after a 5.7% gain in 24 hours, marking its strongest third-quarter performance since 2016 with a 67.57% gain in Q3 2026. This rally occurs despite regulatory setbacks and a Fed rate...
